Viking Therapeutics shares are trading higher after the company announced 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis
Portfolio Pulse from Benzinga Newsdesk
Viking Therapeutics shares are trading higher following the announcement of positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis.
June 04, 2024 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viking Therapeutics shares are trading higher due to positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in NASH patients.
The positive data from the Phase 2b study is a significant milestone for Viking Therapeutics, indicating potential efficacy of VK2809 in treating NASH. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100